ZQ Capital to acquire Allergy Therapeutics for £48m.

Financials

Edit Data

Transaction Value£47m

Consideration TypeCash

Capital Owned-

Capital Bid For100%

EV/Sales-

EV/EBITDA-

Share Price Premium-

One Off Charge-

target

Allergy Therapeutics

bidder

Zq Capital

Sources

Edit

Press Release

ZQ Capital - 16 Oct 2023

Tags

Edit

Private Equity

Friendly

allergy treatments

Pharmaceuticals

Acquisition

Public

Pending

Single Bidder

United Kingdom

Cross Border

Majority

Mandatory Offer

Synopsis

Edit

ZQ Capital, an investment firm, offered to acquire Allergy Therapeutics, a specialty pharmaceutical company focused upon the diagnosis and treatment of allergy, for £48m.

ZQ Capital to acquire Allergy Therapeutics for £48m.

target

bidder

financial advisors

legal advisors

legal advisors

financial advisors

legal advisors